- Onxeo (OTC:OXNXF) announces the confirmation of the preclinical profile of its new drug candidate from platON oligonucleotides platform, OX401, a next-gen PARP inhibitor.
- More news on: Onxeo SA, Healthcare stocks news, Read more ...
home / stock / oxnxf / oxnxf news
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.